Kyriacos A. Mitrophanous
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kyriacos A. Mitrophanous has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Susan M. Kingsman
Oxford BioMedica Ltd., Medawar Centre, Oxford Science Park, Oxford OX4 4GA, UK
2 shared publicationsAlan J. Kingsman
Oxford BioMedica (UK) Ltd, Oxford Science Park, Oxford OX4 4GA, UK2
1 shared publication- Anne-Sophie Hérard
Université Paris-Saclay, Commissariat à l’Énergie Atomique et aux Énergies Alternatives, Translational Research Approaches for Therapeutics, Modeling and Imaging of Neurodegenerative Diseases (TREATMIND) and Molecular Imaging Research Center (MIRCen), Fontenay-aux-Roses, France
1 shared publication - Bechir Jarraya
Cognitive Neuroimaging Unit, CEA, INSERM, Université Paris-Saclay, NeuroSpin Center, Gif-sur-Yvette, France
1 shared publication Caroline Jan
CEA, DSV, I²BM, Molecular Imaging Research Center (MIRCen), F-92265 Fontenay-aux-Roses, France
1 shared publicationDenise M. Day
Oxford BioMedica Ltd., Medawar Centre, Oxford Science Park, Oxford OX4 4GA, UK
1 shared publication
Latest Publications
- 14 October 2009
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 1 (2) , 2ra4
Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia
A gene therapy approach for the treatment of Parkinson’s disease.
- 14 October 2009
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 1 (2) , 2ra4
Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia
A gene therapy approach for the treatment of Parkinson’s disease.
- 26 October 2004
- Published by Springer Nature in Gene Therapy
- Vol. 11 (23) , 1673-1674
Multiple gene products from a single vector: ‘self-cleaving’ 2A peptides
- 26 October 2004
- Published by Springer Nature in Gene Therapy
- Vol. 11 (23) , 1673-1674
Multiple gene products from a single vector: ‘self-cleaving’ 2A peptides
- 7 April 2003
- Published by Springer Nature in Nature Biotechnology
- Vol. 21 (5) , 569-572
Continuous high-titer HIV-1 vector production
Human immunodeficiency virus type 1 (HIV-1)–based vectors are currently made by transient transfection, or using packaging cell lines in which expression of HIV-1 Gag and Pol proteins is induced1,2,3. Continuous vector production by cells in which HIV-1 Gag-Pol is stably expressed would allow rapid and reproducible generation of large vector batches. However, attempts to make stable HIV-1 packaging cells by transfection of plasmids encoding HIV-1 Gag-Pol have resulted in cells which secrete only low levels of p24 antigen (20–80 ng/ml)4,5,6, possibly because of the cytotoxicity of HIV-1 protease7. Infection of cells with HIV-1 can result in stable virus production8; cell clones that produce up to 1,000 ng/ml secreted p24 antigen have been described9. Here we report that expression of HIV-1 Gag-Pol by a murine leukemia virus (MLV) vector allows constitutive, long-term, high-level (up to 850 ng/ml p24) expression of HIV-1 Gag. Stable packaging cells were constructed using codon-optimized HIV-1 Gag-Pol10 and envelope proteins of gammaretroviruses; these producer cells could make up to 107 293T infectious units (i.u.)/ml (20 293T i.u./cell/day) for at least three months in culture.
- 7 April 2003
- Published by Springer Nature in Nature Biotechnology
- Vol. 21 (5) , 569-572
Continuous high-titer HIV-1 vector production
Human immunodeficiency virus type 1 (HIV-1)–based vectors are currently made by transient transfection, or using packaging cell lines in which expression of HIV-1 Gag and Pol proteins is induced1,2,3. Continuous vector production by cells in which HIV-1 Gag-Pol is stably expressed would allow rapid and reproducible generation of large vector batches. However, attempts to make stable HIV-1 packaging cells by transfection of plasmids encoding HIV-1 Gag-Pol have resulted in cells which secrete only low levels of p24 antigen (20–80 ng/ml)4,5,6, possibly because of the cytotoxicity of HIV-1 protease7. Infection of cells with HIV-1 can result in stable virus production8; cell clones that produce up to 1,000 ng/ml secreted p24 antigen have been described9. Here we report that expression of HIV-1 Gag-Pol by a murine leukemia virus (MLV) vector allows constitutive, long-term, high-level (up to 850 ng/ml p24) expression of HIV-1 Gag. Stable packaging cells were constructed using codon-optimized HIV-1 Gag-Pol10 and envelope proteins of gammaretroviruses; these producer cells could make up to 107 293T infectious units (i.u.)/ml (20 293T i.u./cell/day) for at least three months in culture.
- 1 September 2000
- Published by Microbiology Society in Journal of General Virology
- Vol. 81 (9) , 2189-2194
Characterization of the equine infectious anaemia virus S2 protein
S2 is an accessory protein of equine infectious anaemia virus (EIAV), the function of which is unknown. In order to gain insight into the function of S2, the intracellular localization of the protein, its interaction with viral proteins and its incorporation into viral particles have been investigated. Immunolocalization of S2 revealed punctate staining in the cytoplasm and the S2 protein co-precipitated with the EIAV Gag precursor. Despite overexpression of S2 through the use of a codon-optimized sequence, there was no preferential association of S2 with EIAV particles. These data suggest that S2 may function to organize the Gag protein during particle assembly in the cytoplasm but that it is unlikely to be involved in the early stages of the virus life-cycle.
- 1 September 2000
- Published by Microbiology Society in Journal of General Virology
- Vol. 81 (9) , 2189-2194
Characterization of the equine infectious anaemia virus S2 protein
S2 is an accessory protein of equine infectious anaemia virus (EIAV), the function of which is unknown. In order to gain insight into the function of S2, the intracellular localization of the protein, its interaction with viral proteins and its incorporation into viral particles have been investigated. Immunolocalization of S2 revealed punctate staining in the cytoplasm and the S2 protein co-precipitated with the EIAV Gag precursor. Despite overexpression of S2 through the use of a codon-optimized sequence, there was no preferential association of S2 with EIAV particles. These data suggest that S2 may function to organize the Gag protein during particle assembly in the cytoplasm but that it is unlikely to be involved in the early stages of the virus life-cycle.